journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28535939/gene-expression-profiling-of-large-cell-lung-cancer-links-transcriptional-phenotypes-to-the-new-histological-who2015-classification
#1
Anna Karlsson, Hans Brunnström, Patrick Micke, Srinivas Veerla, Johanna Mattsson, Linnea La Fleur, Johan Botling, Mats Jönsson, Christel Reuterswärd, Maria Planck, Johan Staaf
INTRODUCTION: Large cell carcinoma with or without neuroendocrine features (LCNEC and LC, respectively) constitutes a small proportion of non-small cell lung cancer (NSCLC). The WHO2015 classification guidelines changed the definition of the debated histological subtype LC to be based on immunomarkers for adenocarcinoma and squamous cancer. We sought to determine if these new guidelines translate also to the transcriptional landscape of lung cancer, and LC specifically. METHODS: Gene expression profiling was performed using Illumina V4 HT12 microarrays on 159 cases (comprising all histological subtypes including 10 WHO2015 LC and 14 LCNEC tumors), with complimentary mutational and IHC data...
May 20, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28527899/egfr-mutation-analysis-for-prospective-patient-selection-in-two-phase-ii-registration-studies-of-osimertinib
#2
Suzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, Kenneth S Thress, Karen Yu, Rachel Hodge, Susie Weston, Simon Dearden, Sabina Patel, Mireille Cantarini, Frances A Shepherd
INTRODUCTION: Osimertinib is an oral, CNS active, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of EGFR T790M-positive advanced non-small cell lung cancer (NSCLC). Here we evaluate EGFR mutation frequencies in two Phase II studies of osimertinib (AURA extension and AURA2). METHODS: Patients with EGFR mutation-positive advanced NSCLC provided tumor samples following progression on their latest line of therapy for mandatory central T790M testing for study selection criteria...
May 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28506712/lung-metastases-from-esophageal-granular-cell-tumor-an-undoubted-criterion-for-malignancy
#3
Isidro Machado, Julia Cruz, Estanislao Arana, Juan Carlos Peñalver-Cuesta, Miguel Arraras-Martínez, Javier Lavernia, Antonio Llombart-Bosch
No abstract text is available yet for this article.
May 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502724/durable-response-to-afatinib-in-lung-adenocarcinoma-harboring-nrg1-gene-fusions
#4
Nathan D Gay, Ying Wang, Carol Beadling, Andrea Warrick, Tanaya Neff, Christopher L Corless, Khaled Tolba
No abstract text is available yet for this article.
May 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502723/histologic-transformation-in-nsclc-with-pd-1-therapy
#5
Misako Nagasaka, Rahul S Pansare, Eman Abdulfatah, Hui Guan, Paul Tranchida, Shirish M Gadgeel
No abstract text is available yet for this article.
May 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502722/radiotherapy-rescue-of-a-nivolumab-refractory-immune-response-in-a-patient-with-pd-l1-negative-metastatic-squamous-cell-carcinoma-of-the-lung
#6
Zhigang Yuan, Allison Fromm, Kamran A Ahmed, George D Grass, George Q Yang, Daniel E Oliver, Thomas J Dilling, Scott J Antonia, Bradford A Perez
Nivolumab, a PD-1 immune-checkpoint inhibitor antibody, has been approved in the second line for metastatic squamous non-small cell lung cancer (sqNSCLC)(1). However, only a minority of patients respond to anti-PD-1 immunotherapy, and mechanisms of de novo and adaptive resistance to nivolumab are unclear. There are limited treatment options to rescue the immunotherapy refractory status. We herein describe a patient who was nivolumab refractory and subsequently developed global response after a course of palliative thoracic radiotherapy (RT)...
May 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502721/met-exon-14-skipping-mutations-in-lung-adenocarcinoma-clinicopathologic-implications-and-prognostic-values
#7
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-Bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
INTRODUCTION: Response to MET inhibitors in non-small cell lung cancer with MET exon 14 (METex14) skipping has fueled molecular screening efforts and search for optimal therapies. However, further work is needed to refine the clinicopathologic and prognostic implications of METex14 skipping METHODS: Among 795 East-Asian patients who underwent surgery for non-small cell lung cancer, we screened 45 patients with quintuple-negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) lung adenocarcinomas using RT-PCR, and found 17 patients (37...
May 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502850/cost-effectiveness-of-a-bronchial-genomic-classifier-for-the-diagnostic-evaluation-of-lung-cancer
#8
David Feller-Kopman, Shan Liu, Benjamin P Geisler, Malcolm M DeCamp, Jan B Pietzsch
BACKGROUND: The use of a bronchial genomic classifier has been shown to improve the diagnostic accuracy of bronchoscopy for suspected lung cancer by identifying patients who may be more suitable for radiographic surveillance as opposed to undergoing invasive procedures. Our objective was to assess the cost-effectiveness of bronchoscopy plus genomic classifier versus bronchoscopy alone in the diagnostic work-up of patients at intermediate risk for lung cancer. METHODS: A decision-analytic Markov model was developed to project the costs and effects of two competing strategies, using test performance from the AEGIS-1 and AEGIS-2 studies...
May 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28499861/the-cost-effectiveness-of-high-risk-lung-cancer-screening-and-drivers-of-program-efficiency
#9
Sonya Cressman, Stuart J Peacock, Martin C Tammemagi, William K Evans, Natasha B Leighl, John R Goffin, Alain Tremblay, Geoffrey Liu, Daria Manos, Paul MacEachern, Rick Bhatia, Serge Puksa, Garth Nicholas, Annette McWilliams, John R Mayo, John Yee, John C English, Reka Pataky, Emily McPherson, Sukhinder Atkar-Khattra, Michael R Johnston, Heidi Schmidt, Frances A Shepherd, Kam Soghrati, Kayvan Amjadi, Paul Burrowes, Christian Couture, Harmanjatinder S Sekhon, Kazuhiro Yasufuku, Glenwood Goss, Diana N Ionescu, David M Hwang, Simon Martel, Don D Sin, Wan C Tan, Stefan Urbanski, Zhaolin Xu, Ming-Sound Tsao, Stephen Lam
BACKGROUND: Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited. METHODS: Participants in the National Lung Cancer Screening Trial (NLST) were retrospectively identified with the PLCOm2009 risk-prediction tool. The high-risk subgroup was assessed for lung cancer incidences and demographic character compared with the low-risk subgroup and the Pan-Canadian Early Detection of Lung Cancer Study (PanCan)-an observational study, that was high-risk selected in Canada...
May 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28499860/circulating-tumor-dna-identifies-egfr-co-amplification-as-a-mechanism-of-resistance-to-crizotinib-in-a-patient-with-advanced-met-amplified-lung-adenocarcinoma
#10
Ibiayi Dagogo-Jack, David Fabrizio, Jochen Lennerz, Alexa B Schrock, Lauren Young, Mari Mino-Kenudson, Subba R Digumarthy, Rebecca S Heist, Siraj M Ali, Vincent A Miller, Alice T Shaw
No abstract text is available yet for this article.
May 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28487093/expression-of-cdca3-is-a-prognostic-biomarker-and-potential-therapeutic-target-in-non-small-cell-lung-cancer
#11
Mark N Adams, Joshua T Burgess, Yaowu He, Kathy Gately, Cameron Snell, Shu-Dong Zhang, John D Hooper, Derek J Richard, Kenneth J O'Byrne
INTRODUCTION: Non-small cell lung cancer (NSCLC) is the leading cause for cancer-related deaths worldwide. New therapeutic targets are needed as resistance to current treatment, such as platinum-based chemotherapy, are inevitable. The purpose of this study was to determine the functional relevance and therapeutic potential of cell division cycle associated protein-3 (CDCA3) in NSCLC. MATERIALS AND METHODS: The expression of CDCA3 in squamous and non-squamous NSCLC was investigated using bioinformatics, western blot analysis of matched tumour and normal tissue and immunohistochemistry of a tissue microarray...
May 6, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28483607/interleukin-17a-promotes-lung-tumor-progression-through-neutrophil-attraction-to-tumor-sites-and-mediating-resistance-to-pd-1-blockade
#12
Esra A Akbay, Shohei Koyama, Yan Liu, Ruben Dries, Lauren E Bufe, Michael Silkes, Md Maksudul Alam, Dillon M Magee, Robert Jones, Masahisa Jinushi, Meghana Kulkarni, Julian Carretero, Xiaoen Wang, Tiquella Warner-Hatten, Jillian D Cavanaugh, Akio Osa, Atsushi Kumanogoh, Gordon J Freeman, Mark M Awad, David C Christiani, Raphael Bueno, Peter S Hammerman, Glenn Dranoff, Kwok-Kin Wong
HYPOTHESIS: Proinflammatory cytokine Interleukin (IL)-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a pro-tumorigenic inflammatory phenotype, and inhibits anti-tumor immune responses. EXPERIMENTAL DESIGN: We generated bi-transgenic mice expressing a conditional IL-17A allele along with conditional Kras(G12D) and performed immune phenotyping of mouse lungs, survival analysis, and treatment studies with antibodies either blocking PD-1 or IL6, or depleting neutrophils...
May 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28478231/combined-radiotherapy-and-anti-pd-l1-antibody%C3%A2-synergistically-enhances-antitumor-effect%C3%A2-in%C3%A2-non-small-cell-lung-cancer
#13
Xiaomei Gong, Xuefei Li, Tao Jiang, Huikang Xie, Zhengfei Zhu, Fei Zhou, Caicun Zhou
INTRODUCTION: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC. METHODS: The role of the phosphoinositide 3-kinase/protein kinase B signal transducer and activator of transcription 3, epithelial-mesenchymal transition, and tripartite motif containing 21 in regulating PD-L1 expression after radiotherapy was investigated by small interfering-PD-L1-RNA transfection, immunohistochemistry, Western blot, and immunoprecipitation...
May 3, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28461257/the-iaslc-lung-cancer-staging-project-external-validation-of-the-revision-of-the-tnm-stage-groupings-in-the-eighth-edition-of-the-tnm-classification-of-lung-cancer
#14
Kari Chansky, Frank C Detterbeck, Andrew G Nicholson, Valerie W Rusch, Eric Vallières, Patti Groome, Catherine Kennedy, Mark Krasnik, Michael Peak, Lynn Shemanski, Vanessa Bolejack, John J Crowley, Hisao Asamura, Ramón Rami-Porta
INTRODUCTION: Revisions to the tumor, node, and metastasis (TNM) stage classifications for lung cancer, informed by the international database (n=94,708) of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee, need external validation. The objective is to externally validate the revisions using the National Cancer Database (NCDB) of the American College of Surgeons. METHODS: Cases presenting from 2000 through 2012 were drawn from the NCDB and were reclassified according to 8(th) edition stage...
April 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28461256/smoking-history-predicts-sensitivity-to-parp-inhibitor-veliparib-in-patients-with-advanced-non-small-cell-lung-cancer
#15
Martin Reck, Normand Blais, Erzsebet Juhasz, Vera Gorbunova, C Michael Jones, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keilholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dziubinski, Hao Xiong, Rajendar K Mittapalli, Martin Dunbar, Peter Ansell, Lei He, Mark McKee, Vincent Giranda, Suresh S Ramalingam
INTRODUCTION: Tobacco-related non-small cell lung cancer (NSCLC) is associated with reduced survival and greater genomic instability. Veliparib, a potent PARP inhibitor, augments platinum-induced DNA damage. A phase 2 trial of untreated advanced NSCLC showed a trend for improved outcomes (overall survival [OS], HR 0.80, 95% CI: 0.54-1.18; p=0.27; and progression-free survival [PFS], HR 0.72, 95% CI: 0.45-1.15; p=0.17) when veliparib was added to carboplatin/paclitaxel. Here we report an exploratory analysis by smoking history...
April 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28461255/improved-overall-survival-with-aggressive-primary-tumor-radiotherapy-for-patients-with-metastatic-esophageal-cancer
#16
David M Guttmann, Nandita Mitra, Justin Bekelman, James M Metz, John Plastaras, Weiwei Feng, Samuel Swisher-McClure
OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer. METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy (<5040 cGy), chemotherapy plus definitive dose radiotherapy (≥5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score...
April 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28455149/patterns-of-care-and-treatment-outcomes-of-elderly-patients-with-stage-i-esophageal-cancer-analysis-of-the-national-cancer-data-base
#17
Amy C Moreno, Vivek Verma, Wayne L Hofstetter, Steven H Lin
INTRODUCTION: This study analyzes practice patterns, treatment-related mortality, survival, and predictors thereof in elderly patients with early-stage esophageal cancer (EC). METHODS: The National Cancer Data Base (NCDB) was queried for cT1-2 N0 EC in patients ≥ 80 years of age. Patients were divided into four treatment groups: observation (Obs), chemoradiotherapy (CRT), local excision (LE), and esophagectomy (Eso). Patient, tumor, and treatment parameters were extracted and compared...
April 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28428149/local-control-and-toxicity-of-adaptive-radiotherapy-using-weekly-ct-imaging-results-from-the-lartia-trial-in-stage-iii-nsclc
#18
Sara Ramella, Michele Fiore, Sonia Silipigni, Maria Cristina Zappa, Massimo Jaus, Antonio Maria Alberti, Paolo Matteucci, Elisabetta Molfese, Patrizia Cornacchione, Carlo Greco, Lucio Trodella, Edy Ippolito, Rolando Maria D'Angelillo
INTRODUCTION: Anatomical change of tumor during radiotherapy contributes to target missing. However, in the case of tumor shrinkage, adaptation of volume could result in an increased incidence of recurrence in the area of target reduction. This study aims to investigate the incidence of failure of the adaptive approach and, in particular, the risk for local recurrence in the area excluded after replanning. METHODS: In this prospective study, patients with locally advanced NSCLC treated with concomitant chemoradiation underwent weekly chest computed tomography simulation during treatment...
April 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28428148/plasma-ctdna-analysis-for-detection-of-the-egfr-t790m-mutation-in-patients-with-advanced-non-small-cell-lung-cancer
#19
Suzanne Jenkins, James C-H Yang, Suresh S Ramalingam, Karen Yu, Sabina Patel, Susie Weston, Rachel Hodge, Mireille Cantarini, Pasi A Jänne, Tetsuya Mitsudomi, Glenwood D Goss
INTRODUCTION: Tumor biopsies for detecting epidermal growth factor receptor mutations (EGFRm) in advanced non-small cell lung cancer (NSCLC) are invasive, costly and not always feasible for patients with late-stage disease. The clinical utility of the cobas(®) EGFR Mutation Test v2 with plasma samples from patients with NSCLC at disease progression following previous EGFR-tyrosine kinase inhibitor (TKI) therapy was investigated to determine osimertinib treatment eligibility. METHODS: Matched tumor tissue and plasma samples from patients screened for AURA extension and AURA2 phase II studies were tested for EGFRm using tissue- and plasma-based cobas(®) EGFR Mutation Tests v2...
April 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28412495/epidemiology-of-environmental-exposure-and-malignant-mesothelioma
#20
REVIEW
Bian Liu, Maaike van Gerwen, Stefano Bonassi, Emanuela Taioli
Although the association between exposure to asbestos and malignant mesothelioma (particularly malignant pleural mesothelioma) has been well established, the health impact of environmental exposure (EE) to asbestos has been less studied. This review summarizes the most recent studies on the association between malignant mesothelioma and EE with asbestos to identify features associated with EE and quantify the association with malignant mesothelioma. There were 44 studies from 18 countries that met our selection criteria, with a considerable amount of heterogeneity in their study design, measures of exposure, and health outcomes...
April 12, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"